Healthy
Conditions
Keywords
Colon, PYYs, GLP-1, Gut peptides, Fermentation, Lactulose, human
Brief summary
This study will examine the role of the colon as an endocrine organ with a focus on the secretion of gastrointestinal peptides.
Detailed description
This study will examine the role of the colon as an endocrine organ with a focus on the secretion of gastrointestinal peptides. We aim to determine the contribution of the colon to the fasting and postprandial release of gut peptides such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Young healthy men will be examined on three occasions at a clinical research Facility after an overnight fast. On one occasion the colon will also be emptied using a cathartic (picoprep). On two occasions an oral solution of lactulose will be administered to stimulate fermentation by colonic bacteria.
Interventions
OTHERLactulose
Oral solution lactulose (20g lactulose/200mL water).
OTHERPicoprep
Cathartic to accomplish an evacuation of the colonic content.
OTHERPlacebo (water)
oral administration of Water (200mL).
Sponsors
Hvidovre University Hospital
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Healthy men studied on three occasions. Study A and B will be conducted in random order. Day C wil always be conducted as the last study day.
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy young men (self-reported) * BMI between 18,5-24,9 kg/m\^2
Exclusion criteria
* Diabetes mellitus (elevated fasting plasma glucose or HbA1c) * Family history of diabetes mellitus * Intestinal disease (e.g. inflammatory bowel disease, malabsorption) * Family history of intestinal diseases * Previous gastrointestinal surgery * BMI \>25 kg/m\^2 * Tobacco use * Alcohol consumption \> 14 standard drinks/week * Drug use * Kidney, Heart- or Liver disease * Treatment with prescription drugs that can not be held for 12h * Constipation * Accelerated or delayed gastric emptying * Absence of daily bowel movements * Vegetarian lifestyle * \> than 3kgs weightloss or weight gain within 3 months * Haemoglobin concentration \< 8,0mmol/L * Bleeding diathesis * Latex or bandaid allergies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GLP-1 | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of glucagon-like peptide-1 (GLP-1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ghrelin | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of ghrelin |
| PYY | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of peptide YY (PYY) |
| Hydrogen breath test | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Concentrations of hydrogen in exhaled air |
| Neurotensin | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of Neurotensin |
| Glucagon | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of glucagon |
| Motilin | -60, -45, -30, -15, 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210, 225, 240, 255, 270. 285, 300 min | Plasma concentrations of motilin |
Countries
Denmark
Outcome results
None listed